Crispr Therapeutics Ag
Clinical trials sponsored by Crispr Therapeutics Ag, explained in plain language.
Gene-editing biotech developing CRISPR-based therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
CRISPR injection could rewrite the future of blood pressure control
Disease control Recruiting nowThis trial tests an experimental therapy called CTX340, which uses CRISPR gene editing to disable a gene in the liver that regulates blood pressure. It is designed for adults with uncontrolled hypertension despite taking multiple blood pressure medications. The study will first a…
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
CRISPR therapy takes aim at stubborn high cholesterol in first human trial
Disease control Recruiting nowThis early-stage trial tests a new CRISPR-based treatment called CTX310 for people with severe cholesterol and triglyceride problems that don't improve with standard therapies. The treatment uses a tiny fat bubble to deliver gene-editing tools that turn off a gene linked to high …
Phase: PHASE1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Gene-Edited immune cells take on autoimmune blood diseases
Disease control Recruiting nowThis early-stage trial tests a one-time treatment called CTX112, made from donor immune cells edited with CRISPR technology. It aims to safely control two autoimmune diseases where the body attacks its own blood cells: immune thrombocytopenia (ITP) and warm autoimmune hemolytic a…
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
CRISPR gene editing takes on blood cancers: new trial tests donor immune cells
Disease control Recruiting nowThis study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC